Table 3.

Prostate indicators.

1. % of patients evaluated in the clinical session in the Radiation Oncology (RO) department before treatment

2. % of patients with stratification (including PSA, Gleason, TNM)

3. % of patients with MRI staging

4. % of patients presented to the tumour board

5. % of patients with tumour localized with fiducial markers

6. % of patients with tumour localized by CBCT

7. % of patients with tumour localized by ultrasound

8. % of patients who experience an interruption in treatment

9. % of patients completing treatment in the prescribed time

10. % of high risk patients receiving long-term hormonotherapy

11. % of high risk patients receiving boost brachytherapy

12. Time elapsed between first visit at RO department and initiation of any type of treatment

13. Time elapsed between first visit at RO department and start of radiotherapy (EBRT, BRT)

14. Time elapses between CT simulation and start of radiotherapy (EBRT, BRT)

15. % of patients treated using new technologies (IMRT)

16. % of patients treated using new technologies (VMAT)

17. % of patients treated using new technologies (SBRT)

18. % of EBRT sessions with imaging controls performed during the treatment (kV, MV, CBCT, MVCT)

19. % of patients with rectal mucositis (grade 2 or 3) (less than 6 months)

20. % of patients with rectal mucositis (grade 2 or 3) (more than 6 months)

21. % of patients with cystitis-urethritis (grade 2 or 3) (less than 6 months)

22. % of patients with cystitis-urethritis (grade 2 or 3) (more than 6 months)

23. Biochemical survival

24. Regular follow-up after the treatment (Yes/No)

25. Regular follow-up during the treatment (Yes/No)